NCT00502671View on ClinicalTrials.gov

A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.

PHASE4CompletedINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Colorectal Cancer
Interventions
DRUG

capecitabine [Xeloda]

1250mg/m2 po bid on days 1-14 of each 3 week cycle

Trial Locations (46)

105229

Moscow

107005

Moscow

119992

Moscow

123354

Moscow

127006

Moscow

143420

Moscow

156005

Kostroma

163045

Arkhangelsk

170008

Tver'

173016

Novgorod Veliky

197022

Saint Petersburg

197047

Saint Petersburg

214000

Smolensk

248007

Kaluga

249036

Obninsk

305035

Kursk

308010

Belgorod

344037

Rostov-on-Don

350040

Krasnodar

354057

Sashi

355047

Stavropol

390011

Ryazan

398005

Lipetsk

400138

Volgograd

414041

Astrakhan

420029

Kazan'

420111

Kazan'

426009

Izhevsk

443031

Samara

445846

Tollyatti

450005

Ufa

450054

Ufa

454047

Chelyabinsk

460021

Orenburg

603126

Nizhny Novgorod

610021

Kirov

620905

Yekaterinburg

625047

Tyumen

628408

Surgut

629001

Salekhard

634028

Tomsk

634050

Tomsk

656049

Barnaul

664035

Irkutsk

693010

Yuzhno-Sakhalinsk

614 066

Perm

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00502671 - A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer. | Biotech Hunter | Biotech Hunter